| ID | 1019 |
| Name of the vaccine | DT Polio Adsorbed |
| Microbe | Bacteria |
| Disease name | Diphtheria |
| Name of bacteria | Corynebacterium diphtheriae |
| Type of vaccine | Combination |
| Nucleic acid content | DNA |
| Age | 7 years and older |
| Description of the vaccine | Diphtheria, tetanus and inactivated poliovirus vaccine. |
| Name of the manufacturer | Sanofi Pasteur Ltd |
| Name of the manufacturing country | Canada |
| Year of manufacture | NA |
| Clinical Phase status | Approved |
| Bacterial strain | Gram-positive bacillus. |
| Efficacy | 99.3% seroprotection rate. |
| Vaccine formulation | Suspension for injection |
| Dosage | Given as a second booster. |
| Mechanism of action | Seroprotective threshold of 0.1 IU/mL. |
| Route of administration | Intramuscular |
| Indications | NA |
| Export | NA |
| Approval | NA |
| Adjuvant | Aluminium phosphate |
| Repurposing | For tetanus and inactivated poliovirus. |
| Side effects of vaccine | Erythema, pain and swelling. |
| Post vaccination | NA |
| Dose type | Single dose |
| Interspecies transfer | NA |
| PubMed identifier | 21441781 |
| Clinical trial number | NA |
| Reference | http://www.violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=563&keywords= |
| Other name | NA |
| Additional Links | NA
|